Lazard Asset Management
ACET icon

Lazard Asset Management’s Adicet Bio ACET Stock Holding History

Lazard Asset Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-26
Closed – – 2278
2024
Q4 		$0 Hold
26
– – ﹤0.01% 2251
2024
Q3 		$0 Sell
26
-14
-35% -$313 ﹤0.01% 2243
2024
Q2 		$0 Sell
40
-298
-88% -$7.99K ﹤0.01% 2204
2024
Q1 		$12K Buy
338
+169
+100% +$6.99K ﹤0.01% 1867
2023
Q4 		$5K Sell
169
-22
-12% -$480 ﹤0.01% 2119
2023
Q3 		$4K Buy
191
+9
+5% +$318 ﹤0.01% 2179
2023
Q2 		$6K Hold
182
– – ﹤0.01% 2203
2023
Q1 		$16K Buy
182
+128
+237% +$16.1K ﹤0.01% 2084
2022
Q4 		$7K Buy
+54
New +$13.5K ﹤0.01% 2226
2022
Q3 		– Sell
-354
Closed -$82K – 2281
2022
Q2 		$82K Buy
+354
New +$77.7K ﹤0.01% 1584

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Lazard Asset Management's ACET Position: Q1 2025 in Review

Lazard Asset Management sold out of Adicet Bio (ACET) in Q1 2025, closing a stake of 26 shares.

Lazard Asset Management first reported a position in ACET in Q2 2022 and held it in 10 quarters. The position peaked at $82K in Q2 2022. 56 funds tracked by Wall St. Rank hold ACET as of Q1 2025.

  • Lazard Asset Management reported no remaining Adicet Bio position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 26 Adicet Bio shares in Q1 2025.
  • Lazard Asset Management first reported a position in Adicet Bio in Q2 2022 and held it in 10 quarters.
  • Lazard Asset Management's Adicet Bio position peaked at $82K in Q2 2022.
  • 56 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.